P01.021 Comprehensive Geriatric Assessment (CGA) for outcome prediction in elderly patients (PTS)with glioblastoma (GBM): a mono-institutional experience

Por Lombardi, G, Bergo, E, Bellu, L, Caccese, M, Lettiero, A, Tierno, G, Pambuku, A, Brunello, A, Zagonel, V
Publicado no Neuro Oncol (2018)

P01.118 Prognostic factors and management of gliomatosi cerebri (GC) from real life experience of two neuroncology centers

Por Lombardi, G, Bellu, L, Sabatino, G, Caccese, M, Berti, F, Busato, F, Della Puppa, A, D’Avella, D, Olivi, A, Zagonel, V
Publicado no Neuro Oncol (2018)

P01.018 Mismatch repair deficiency (MMRd) in glioma patients (PTS): frequency and correlation with clinical, histological and molecular characteristics

Por Lombardi, G, Caccese, M, Simonelli, M, Fassan, M, Persico, P, Lorenzi, E, Bertorelle, R, Gardiman, M, Bellu, L, Pambuku, A, Santoro, A, Zagonel, V
Publicado no Neuro Oncol (2018)

P01.040 Identification of a predictive biomarker of response to regorafenib in relapsed glioblastoma patients <REGOMA trial>

Por Lombardi, G, Indraccolo, S, de Salvo, G, Verza, M, Magni, G, Eoli, M, Rudà, R, Franceschi, E, Faedi, M, Lolli, I, Rizzato, S, Caccese, M, Gardiman, M, Zagonel, V
Publicado no Neuro Oncol (2018)

ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations

Por Peretti, U., Ferrara, R., Pilotto, S., Kinspergher, S., Caccese, M., Santo, A., Brunelli, M., Caliò, A., Carbognin, L., Sperduti, I., Garassino, M., Chilosi, M., Scarpa, A., Tortora, G., Bria, E.
Publicado no Respir Res (2016)

OS2.3 Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma <GBM> patients <PTS>

Por Lombardi, G, de Salvo, G, Rudà, R, Franceschi, E, Eoli, M, Faedi, M, Pace, A, Lolli, I, Rizzato, S, Germano, D, Pasqualetti, F, Farina, M, Magni, G, Bellu, L, Caccese, M, Pambuku, A, Bergo, E, Indraccolo, S, Gardiman, M, Soffietti, R, Zagonel, V
Publicado no Neuro Oncol (2018)